, a bio/informatics shared resource is still "open for business" - Visit the CDS website

B. Paudel
PhD Candidate
Last active: 10/9/2019

B. B Paudel, B.S., Ph.D.

Official Affiliation: Biochemistry

Profile

We use systematic approach to understand how cancer cells respond to therapies. By utilizing high-throughput microscopy, image analysis, experimental techniques, and mathematical modeling, we examine the drug response behaviors of cancer cells and how they evolve during therapy- both an early and long term response. 

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Dynamics of drug response informs rational combination regimens. Paudel BB, Quaranta V (2019) Sci Signal 12(595)
    › Primary publication · 31431544 (PubMed)
  2. Quantifying Drug Combination Synergy along Potency and Efficacy Axes. Meyer CT, Wooten DJ, Paudel BB, Bauer J, Hardeman KN, Westover D, Lovly CM, Harris LA, Tyson DR, Quaranta V (2019) Cell Syst 8(2): 97-108.e16
    › Primary publication · 30797775 (PubMed) · PMC6675406 (PubMed Central)
  3. Metabolic plasticity meets gene regulation. Paudel BB, Quaranta V (2019) Proc Natl Acad Sci U S A 116(9): 3370-3372
    › Primary publication · 30737291 (PubMed) · PMC6397587 (PubMed Central)
  4. A Nonquiescent "Idling" Population State in Drug-Treated, BRAF-Mutated Melanoma. Paudel BB, Harris LA, Hardeman KN, Abugable AA, Hayford CE, Tyson DR, Quaranta V (2018) Biophys J 114(6): 1499-1511
    › Primary publication · 29590606 (PubMed) · PMC5883941 (PubMed Central)
  5. Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition. Hardeman KN, Peng C, Paudel BB, Meyer CT, Luong T, Tyson DR, Young JD, Quaranta V, Fessel JP (2017) Sci Rep : 42604
    › Primary publication · 28205616 (PubMed) · PMC5311997 (PubMed Central)
  6. An unbiased metric of antiproliferative drug effect in vitro. Harris LA, Frick PL, Garbett SP, Hardeman KN, Paudel BB, Lopez CF, Quaranta V, Tyson DR (2016) Nat Methods 13(6): 497-500
    › Primary publication · 27135974 (PubMed) · PMC4887341 (PubMed Central)
  7. Quantifying heterogeneity and dynamics of clonal fitness in response to perturbation. Frick PL, Paudel BB, Tyson DR, Quaranta V (2015) J Cell Physiol 230(7): 1403-12
    › Primary publication · 25600161 (PubMed) · PMC5580929 (PubMed Central)

Featured Affiliations

View all affiliations

Contact Information

No address provided
6155852379 (p)
Email

Keywords & MeSH Terms

MeSH terms are retrieved from PubMed records. Learn more.

Key: MeSH Term Keyword

Adaptation, Physiological Antineoplastic Agents Biochemical Phenomena Cancer Research Cell Culture Techniques Cell Line Cell Line, Tumor Clonal Heterogeneity Clone Cells Computer Simulation Cycloheximide Drug Combinations Drug Resistance, Neoplasm Drug Response Dynamics Drug Synergism Epigenesis, Genetic Gene Expression Regulation Genetic Fitness Genetic Heterogeneity Glucose Humans Indoles Mathematical Modeling Metabolic Networks and Pathways Molecular Targeted Therapy Mutation Neoplasms Pharmacogenomic Variants Phenotype Protein Synthesis Inhibitors Proto-Oncogene Proteins B-raf Sensitivity and Specificity Small Molecule Libraries Sulfonamides Systems Biology Time Factors Treatment Outcome